文献速递神经肿瘤神经重症

脑膜瘤与胶质母细胞瘤患者存在系统性凝血激活

Systemic coagulation is activated in patients with meningioma and glioblastoma.
PubMed 文献 · J Neurooncol · 2021-10-15

研究采用校准自动血栓图检测胶质母细胞瘤(GBM)和脑膜瘤患者的凝血酶生成峰值,发现两类患者术前峰值均高于健康对照,GBM更显著;9例GBM患者术后峰值显著下降,且术前峰值与肿瘤体积或总生存无关。

要点

  • GBM和脑膜瘤患者术前凝血酶生成峰值均高于健康对照。
  • GBM患者术后凝血酶生成峰值较术前显著降低。
  • 术前凝血酶生成峰值与肿瘤体积或总生存无关联。

核心结论

  • 脑膜瘤和GBM均诱导系统性凝血激活,GBM程度更高。
  • GBM切除后凝血激活显著下降。
  • 术前凝血酶生成峰值与肿瘤体积或总生存无关。

研究设计与样本

  • 前瞻性获取连续GBM患者术前和术后血浆样本,脑膜瘤患者及年龄性别匹配的健康献血者对照各采集一次。
  • 使用校准自动血栓图(CAT)检测凝血酶生成峰值,术前MRI测量肿瘤体积。
  • GBM患者术前峰值与对照比较,9例有配对数据的GBM患者比较术前与术后峰值。

主要发现

  • GBM患者术前凝血酶生成峰值高于对照(288.6 ± 54.1 nM vs 187.1 ± 41.7 nM,P < 0.001)。
  • 9例配对GBM患者术后峰值较术前显著降低(323 ± 38 nM vs 265 ± 52 nM,P = 0.007)。
  • 脑膜瘤患者凝血酶生成峰值高于对照(242.2 ± 54.9 nM vs 177.7 ± 57.0 nM,P < 0.001)。
  • 凝血酶生成峰值与术前肿瘤体积或总生存无关联。

临床怎么用

  • GBM和脑膜瘤患者应意识到存在系统性凝血激活及VTE风险。
  • GBM切除可能降低凝血激活,术后可结合凝血酶生成峰值评估。
  • 术前凝血酶生成峰值不宜用于预测肿瘤体积或总生存。

局限性

  • GBM配对术前术后数据分析仅9例。
  • 脑膜瘤患者仅单次采血,无术后配对数据。
  • 未报告VTE事件与凝血酶生成峰值的直接关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Up to 30% of patients with glioblastoma (GBM) develop venous thromboembolism (VTE) over the course of the disease. Although not as high, the risk for VTE is also increased in patients with meningioma. Direct measurement of peak thrombin generation (TG) allows quantitative assessment of systemic coagulation activation in patients with GBM and meningioma. Our aim was to determine the extent of systemic coagulation activation induced by brain tumors, to measure the shift between pre- and post-operative peak TG in patients with GBM, and to assess the relationship between pre-surgical peak TG and pre-operative brain tumor volume on imaging. METHODS: Pre- and post-surgical plasma samples were obtained from successive patients with GBM and once from patients with meningioma and healthy age- and sex-matched blood donor controls. TG was measured using the calibrated automated thrombogram (CAT) assay, and tumor volumes were measured in pre-surgical MRI scans. RESULTS: Pre-surgical peak TG was higher in patients with GBM than in controls (288.6 ± 54.1 nM vs 187.1 ± 41.7 nM, respectively, P < 0.001), and, in the nine patients with GBM and paired data available, peak TG was significantly reduced after surgery (323 ± 38 nM vs 265 ± 52 nM, respectively, P = 0.007). Similarly, subjects with meningioma demonstrated higher peak TG compared to controls (242.2 ± 54.9 nM vs 177.7 ± 57.0 nM, respectively, P < 0.001). There was no association between peak TG and pre-operative tumor volume or overall survival. CONCLUSION: Our results indicate that systemic coagulation activation occurs with both meningioma and GBM, but to a greater degree in the latter. Preoperative peak TG did not correlate with tumor volume, but removal of GBM caused a significant decrease in coagulation activation.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Yerrabothala S, Gourley BL, Ford JC, et al. Systemic coagulation is activated in patients with meningioma and glioblastoma. J Neurooncol. 2021. PMID: 34652553. doi:10.1007/s11060-021-03865-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。